Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target

Oct 6, 2026, 10:16 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $15 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 5, 2026, 8:10 PMBenzinga Newsdesk
Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly
KRRO
SEC EDGAROct 5, 2026, 8:10 PMSEC EDGAR
8-K filing — Korro Bio, Inc. (KRRO)
Filed: 2026-10-05 AccNo: 0001193125-26-414118 Size: 232 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
KRRO
BenzingaAug 19, 2026, 8:11 PMBenzinga Newsdesk
Korro Bio Submits To Australian Alfred Health Human Ethics Committee To Start Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
https://www.sec.gov/ix?doc=/Archives/edgar/data/1703647/000119312526356877/krro-20260819.htm
KRRO